Mysterious Brand-New Heart Syndrome Reportedly Affects 90% of U.S. Population
COVID Propaganda Roundup: The latest updates on the “new normal” – chronicling the lies, distortions, and abuses by the ruling class.
By Ben Bartee
Global Research, May 14, 2024
Brand-new heart syndrome reportedly affects 90% of U.S. population, American Medical Association claims, no explanation offered
Via American Heart Association, October 2023 (emphasis added):
“Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association’s flagship journal Circulation.
Various aspects of cardiovascular disease that overlap with kidney disease, Type 2 diabetes and obesity support the new approach. For the first time, the American Heart Association defines the overlap in these conditions as cardiovascular-kidney-metabolic (CKM) syndrome. People who have or are at risk for cardiovascular disease may have CKM syndrome…
According to the American Heart Association’s 2023 Statistical Update, 1 in 3 U.S. adults have three or more risk factors that contribute to cardiovascular disease, metabolic disorders and/or kidney disease. CKM affects nearly every major organ in the body, including the heart, brain, kidney and liver. However, the biggest impact is on the cardiovascular system, affecting blood vessels and heart muscle function, the rate of fatty buildup in arteries, electrical impulses in the heart and more.”
Mass Protest Against the US-backed Regime Change in Pakistan
Although the diagnostic designation CKM only materialized last fall, according to recently released data from the Journal of the American Medical Association, a full 90% of Americans might be afflicted.
Via Healthline (emphasis added):
“A new study has revealed that roughly 90% of Americans may have cardiovascular-kidney-metabolic (CKM) syndrome.
The risks are greatest among older adults, men, and Black individuals, the report, which was published in JAMA Wednesday, found.
The American Heart Association (AHA) introduced a new staging system in 2023 — called CKM syndrome — to better treat and manage cardiovascular, kidney, and metabolic diseases, since they are deeply connected and often require a multidisciplinary approach.
CKM syndrome is a systemic disorder that has links between heart disease, kidney disease, diabetes, and obesity.”
Via Journal of the American Medical Association (emphasis added):
“Almost 90% of US adults met criteria for CKM syndrome (stage 1 or higher) and 15% met criteria for advanced stages, neither of which improved between 2011 and 2020. The lack of progress, in part, may reflect concomitant improvement and worsening of different risk factors over time. Substantial between-subgroup differences in advanced stages were observed, with older age, men, and Black adults at increased risk.”
A 90% diagnosis rate for a newborn medical condition impacting multiple organs simultaneously would seem to beg for deep, deliberate, comprehensive reflection within the medical community — the kind of sweeping mobilization of resources seen during Operation Warp Speed — to ferret out root causes, which in other contexts, like mass migration, the likes of the Karamel-uh entity are exceptionally curious about.
…Unless, of course, true healthcare isn’t the overriding objective of the brand of institutionalized, corporatized “healthcare” championed by the governing authorities and industry.
One doesn’t require an epidemiology degree to get the sense that whatever is triggering functional meltdowns in multiple organs at once in 90% of a population is probably something coming from a source ubiquitous in the environment, like the food supply, or the water, or the tip of a syringe filled with a certain experimental gene therapy — or all three at once.
Yet — and you’ll be shocked to learn this — perusing all of the literature on CMK pushed out by mainstream outlets and medical organizations like the AMA, there is a palpable lack of interest in asking fundamental questions.
What they are interested in, and what we can expect coming down the pipeline, is new patented drugs for CMK to the great ecstasy of Pfizer and Merck shareholders.
“An ounce of prevention is worth a pound of cure” is anathema to the industry’s business model, so what we get is the inverse paradigm.
